FDA requires more postmarket data to keep certain devices on the market

The FDA would require medtech companies seeking certain premarket approvals to submit timely postmarket study data or risk losing those approvals. The requirement is part of a final guidance the agency released last week, detailing how it will consider uncertainty in making benefit-risk determinations on breakthrough device PMAs, de novo classifications and humanitarian device exemptions (HDEs).